Posters on the topic "New clinical developments in prophylactic and acute medications"

Back
  • P013
  • ePoster
Establishing relationships between efficacy, tolerability and the serum concentration of candesartan when used as migraine prophylaxis
  • Hedda Skogum Riise (Trondheim, NO)
  • P014
  • ePoster
Vaporized Cannabis versus placebo for acute migraine – a randomized controlled trial
  • P015
  • ePoster
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine – a retrospective, observational, multicenter, cohort study
  • P016
  • ePoster
Role of SphenoCath procedure in the treatment of migraine – a retrospective study
  • P017
  • ePoster
Use of Rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in monthly migraine days – a pooled analysis of 2 open-label trials
  • P018
  • ePoster
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective clinical study based on the stratification of responders to Erenumab
  • P019
  • ePoster
Rimegepant effectiveness and tolerability as acute migraine treatment (GAINER) – a real-world multicentric study
  • P020
  • ePoster
GLP-1 agonists for the treatment of chronic migraine: a pilot prospective observational cohort study
  • P021
  • ePoster
Real-world experience of Lasmiditan for the acute treatment of migraine – a single clinic-based prospective study
  • P022
  • ePoster
Conditioned pain modulation is associated with the prognosis in patients with migraine
  • P023
  • ePoster
Patients satisfaction to triptans and to available oral and injectable medications (OnabotulinumtoxinA/anti-CGRP MAbs) for migraine prophylaxis. Results of a web-based survey
  • P024
  • ePoster
Migraine patients treating with remote electrical neuromodulation (REN) shows significant and clinically meaningful benefits and utilization in a Coverage with evidence development (CED) study
  • P284
  • ePoster
Intravenous dihydroergotamine for primary headache disorders: factors to consider for an optimal outcome – a service evaluation
  • P285
  • ePoster
Rimegepant for the acute treatment of migraine – a phase 3, multicenter, open-label, long-term safety study in adults from China
  • P286
  • ePoster
Moderate to vigorous intensity exercise for cluster headaches: insights from case summaries and literature review
  • P287
  • ePoster
Intravenous valproic acid treatment in patients with chronic refractory migraine: our experience in pediatric age
    • v1.20.0
    • © Conventus Congressmanagement & Marketing GmbH